{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:25Z","timestamp":1791357385653,"version":"4.3.1"},"reference-count":25,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T00:00:00Z","timestamp":1470441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Can J Psychiatry"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>A systematic review was conducted to examine the efficacy, tolerability, and acceptability of asenapine compared with other antipsychotics in the treatment of psychotic disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Four databases, 8 trial registries, and conference presentations were searched for randomized clinical trials of asenapine versus any comparator for the treatment of any psychotic illness. Primary outcome measures were changes in the Positive and Negative Syndrome Scale (PANSS) total score and the incidence of withdrawal due to adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Eight randomized clinical trials, encompassing 3765 patients, that compared asenapine with placebo ( n = 5) and olanzapine ( n = 3) were included. No differences were found between asenapine and olanzapine in terms of changes to PANSS total or PANSS negative subscale scores. Patients taking asenapine were more likely to experience worsening schizophrenia and\/or psychosis than were those taking olanzapine. No differences were found between asenapine and olanzapine in rates of discontinuation due to adverse drug reactions or lack of efficacy, but those taking asenapine had higher rates of withdrawal for any reason than those taking olanzapine. Asenapine caused less clinically significant weight gain or increases in triglycerides than olanzapine and was more likely to cause extrapyramidal symptoms than olanzapine. In comparison to placebo, either no difference or superiority was demonstrated in favour of asenapine on all efficacy measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The current evidence is limited, as asenapine has been compared only with placebo or olanzapine. In the randomized clinical trials analysed, asenapine was similar or superior to placebo and similar or inferior to olanzapine on most efficacy outcomes. While asenapine demonstrated fewer adverse metabolic outcomes than olanzapine, rates of extrapyramidal symptom\u2013related adverse effects were higher.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0706743716661324","type":"journal-article","created":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T23:24:44Z","timestamp":1470093884000},"page":"123-137","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Asenapine for the Treatment of Psychotic Disorders"],"prefix":"10.1177","volume":"62","author":[{"given":"Catherine","family":"Orr","sequence":"first","affiliation":[{"name":"Pharmacy Department, London Health Sciences Centre, London, Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Pharmacy Department, London Health Sciences Centre, London, Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Sawh","sequence":"additional","affiliation":[{"name":"Pharmacy Department, London Health Sciences Centre, London, Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Jones","sequence":"additional","affiliation":[{"name":"Departments of Anesthesia & Peri-operative Medicine and Epidemiology & Biostatistics, Western University, London, Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamini","family":"Vasudev","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Medicine, Western University, London, Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,8,6]]},"reference":[{"key":"bibr1-0706743716661324","unstructured":"Public Health Agency of Canada. Schizophrenia [Internet]. 2012 [cited 2013 Sep 7]. http:\/\/www.phac-aspc.gc.ca\/publicat\/miic-mmac\/chap_3-eng.php"},{"key":"bibr2-0706743716661324","unstructured":"Crismon L, Argo TR, Buckley PF. Chapter 76. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 8th ed [Internet]. 2011 [cited 2013 Sep 7]. Available from: http:\/\/www.accesspharmacy.com\/content.aspx?aID=7987911"},{"key":"bibr3-0706743716661324","unstructured":"Merck. Saphris: drug product monograph [Internet]. In: e-CPS. Ottawa (ON): Canadian Pharmacist Association; 2011 [cited 2013 Sep 7]. Available from: https:\/\/www.e-therapeutics.ca\/cps.select.preliminaryFilter.action?simplePreliminaryFilter=asenapine+maleate#"},{"key":"bibr4-0706743716661324","unstructured":"Lilly. Zyprexa [Internet]. In: e-CPS. Ottawa (ON): Canadian Pharmacist Association; 2013 [cited 2013 Sep 7]. Available from: https:\/\/www.e-therapeutics.ca\/cps.select.preliminaryFilter.action?simplePreliminaryFilter=olanzapine"},{"key":"bibr5-0706743716661324","unstructured":"Health Canada, Drug Product Database. Saphris drug product monograph. Kirkland (QC): Merck Canada Inc; 2011."},{"key":"bibr6-0706743716661324","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-012-0009-0"},{"key":"bibr7-0706743716661324","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11r07596"},{"key":"bibr8-0706743716661324","doi-asserted-by":"crossref","unstructured":"Mills E, Thorlund K, Loannidis J. Research methods and reporting: demystifying trial networks and network meta analysis [Internet]. BMJ 2013 [cited 2014 Nov 20]. Available from: http:\/\/www.bmj.com\/content\/346\/bmj.f2914","DOI":"10.1136\/bmj.f2914"},{"key":"bibr9-0706743716661324","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08030368"},{"key":"bibr10-0706743716661324","doi-asserted-by":"publisher","DOI":"10.2165\/11634500-000000000-00000"},{"key":"bibr11-0706743716661324","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"bibr12-0706743716661324","unstructured":"Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. Section 16.5.4: Studies with more than two intervention groups In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions (Version 5.1.0) [Internet]. The Cochrane Collaboration [cited 2014 May 15]. Available from: http:\/\/handbook.cochrane.org\/"},{"key":"bibr13-0706743716661324","unstructured":"Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. Section 10.4.4.1: Comparing fixed and random effects estimates. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions (Version 5.1.0) [Internet]. The Cochrane Collaboration [cited 2015 Jun 6]. Available from: http:\/\/handbook.cochrane.org\/"},{"key":"bibr14-0706743716661324","unstructured":"Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions [Internet]. Version 5.1.0 [updated March 2011]. London (UK): The Cochrane Collaboration; 2011 [cited 2014 Mar 20]. Available from: http:\/\/handbook.cochrane.org\/"},{"key":"bibr15-0706743716661324","unstructured":"Higgins JPT, Deeks JJ. Chapter 10: Addressing reporting biases. Section 10.4.3.1: Recommendations on testing for funnel plot asymmetry. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions (Version 5.1.0) [Internet]. The Cochrane Collaboration [cited 2016 Jun 20]. Available from: http:\/\/handbook.cochrane.org\/"},{"key":"bibr16-0706743716661324","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31823f880a"},{"key":"bibr17-0706743716661324","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181d35d6b"},{"key":"bibr18-0706743716661324","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10m06306"},{"key":"bibr19-0706743716661324","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1004"},{"key":"bibr20-0706743716661324","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1248313"},{"key":"bibr21-0706743716661324","first-page":"1297","volume":"49","author":"Chapel S","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"bibr22-0706743716661324","unstructured":"Laughren T. Department of Health and Human Services Public Health Service Food and Drug Administration, Center for Drug Evaluation and Research. Recommendation for approval action for asenapine sublingual tablets for the acute treatment of schizophrenia and for the acute treatment of mania or mixed episodes in bipolar 1 disorder 2009 (22-117) [Internet] [cited 2014 Apr 10]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022117s000_MedR_P1.pdf"},{"key":"bibr23-0706743716661324","unstructured":"Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Australian public assessment report for asenapine [Internet]. 2011 [cited 2014 Apr 10]. Available from: http:\/\/www.tga.gov.au\/auspar\/auspar-asenapine"},{"key":"bibr24-0706743716661324","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement [Internet]. PLoS Med. 2009;6(6):e1000097 [cited 2013 Dec]. Available from: http:\/\/www.prisma-statement.org\/index.htm","DOI":"10.1371\/journal.pmed.1000097"},{"key":"bibr25-0706743716661324","unstructured":"Higgins JPT, Deeks JJ, editors. Chapter 7: Selecting studies and collecting data. Section 7.2.4: Implementation of the selection process. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions (Version 5.1.0) [Internet]. The Cochrane Collaboration [cited 2015 Jun 4]. Available from: http:\/\/handbook.cochrane.org\/"}],"container-title":["The Canadian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0706743716661324","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0706743716661324","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0706743716661324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:14:25Z","timestamp":1777392865000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0706743716661324"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2016,8,6]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1177\/0706743716661324"],"URL":"https:\/\/doi.org\/10.1177\/0706743716661324","relation":{},"ISSN":["0706-7437","1497-0015"],"issn-type":[{"value":"0706-7437","type":"print"},{"value":"1497-0015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,6]]}}}